Concepedia

Adam Giermasz

AG

Statistics

Publications

37

Citations

1.9K

H-Index

21

Active since

1995

Affiliations

Medical University of Warsaw(Current)

University of California, Davis

Pfizer (United States)

University of California, San Francisco

University of Michigan

Adam Giermasz is an author at Medical University of Warsaw specializing in medicine, immunology, and tumor biology.

Top concepts

Publications per year

1995–2025

37

Publications

37

Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant

Lindsey A. George, Spencer K. Sullivan, Adam Giermasz et al. · New England Journal of Medicine · 2017 · 736 citations · Full text

Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice.

Wojciech Feleszko, Ewa Bałkowiec-Iskra, Anna Czajka et al. · PubMed · 2000 · 134 citations

, , +17

Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B

Annette von Drygalski, Adam Giermasz, Giancarlo Castaman et al. · Blood Advances · 2019 · 124 citations · Full text

Lovastatin and tumor necrosis factor-? exhibit potentiated antitumor effects against Ha-ras-transformed murine tumorVia inhibition of tumor-induced angiogenesis

Wojciech Feleszko, Ewa Z. Ba kowiec, Elisabeth Sieberth et al. · International Journal of Cancer · 1999 · 93 citations

, , +16

Activity of transgene-produced B-domain–deleted factor VIII in human plasma following AAV5 gene therapy

S. Rosén, Stefan Tiefenbacher, Mary Robinson et al. · Blood · 2020 · 66 citations · Full text

1–5 of 37